Characterisation of genotype-molecular phenotype interactions to provide a platform for genetically validated drug discovery and development in NAFLD

点击翻译按钮获取中文摘要

Liver disease caused by excess fat in the liver is increasingly common and can lead to liver cirrhosis, cancer and death. There are currently no drug treatments available for the condition. Studies have identified common genetic changes which increase the chance of developing fatty liver though it is unclear how they do this. Understanding the link between genetics and disease provides an opportunity to develop new and effective drugs. In this project GlaxoSmithKline will partner with Imperial College London to use state-of-the-art technology to carefully examine levels of different genes in the liver samples from patients with fatty liver disease. These data will be used to understand how gene variants cause disease, how genes may be targeted by new drugs to treat disease and in which patients they may be most effective.